Background & Objective: There are many factors affect the prognosis of the patients with unresectable esophageal carcinoma who underwent intubation, however, it is unclear which ones are main causes so far. This study was designed to analyze the prognostic factors of unresectable esophageal carcinoma after stenting in order to find the reasonable modalities of palliative therapy.
Methods: Consecutive 102 patients with unresectable esophageal carcinoma who were eligible for inclusion criteria were analyzed after stenting. Twelve factors including gender, age tumor site, tumor length, stricture degree in diameter, pathologic type, grade of cell differentiation, clinical tumor stage (T, N, M), pre-stenting therapy and post-stenting therapy (radiotherapy and/or chemotherapy) were used for Cox regression model analysis. The survival rate was calculated by life table.
Results: The technical sucess rate of stenting was 98.3%. There were significant improvement on the grade of swallowing function (P = 0.000) and quality of life (KPS scores, P = 0.000). The incidence rate of complications was 43.1% (44/102). The survival rates of 3, 6, 9, 12 months were 67.53%, 40.59%, 27.43%, and 18.65%, respectively. The results of Cox regression showed that invasion degree of primary tumor (T, P = 0.0410) and distal metastasis (M, P = 0.006) were the statistically significant prognostic factors. The odds ratio(ORT) was 1.750 (95% CI, 0.996-3.074) on T stage of primary carcinoma, ORM was 1.527 (95% CI, 1.126-2.069) on M stage. There was no statistical significance in the survival of the patients affected by radiotherapy and/or chemotherapy after intubation.
Conclusion: T stage and M stage are the major prognostic factors affecting the survival of patients with unresectable esophageal carcinoma after stenting. There is no benefit for survival of patients treated with radiotherapy and/or chemotherapy after intubation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma.
Dis Esophagus
January 2025
Department of Esophageal Surgery, National Cancer Center, Tokyo, Japan.
Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable (T4) esophageal squamous cell carcinoma (ESCC), but the prognosis is poor. Borderline resectable (T3br) ESCC has been discussed, but its clinical features and appropriate treatment are unclear. The effects of docetaxel plus cisplatin and 5-fluorouracil (DCF) therapy and subsequent surgery for potentially unresectable ESCC remain controversial.
View Article and Find Full Text PDFThe efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma.
BMC Cancer
January 2025
Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao, Shandong Province, China.
Purpose: To evaluate the efficacy and safety of induction chemotherapy combined with programmed death protein 1 (PD-1) inhibitor (sintilimab) followed by concurrent chemoradiotherapy (CCRT) plus sintilimab, and subsequent maintenance with sintilimab (IC-ICCRT-IO) for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in a retrospective study.
Methods: Data from patients with histologically confirmed, locally advanced, inoperable ESCC who received IC-ICCRT-IO were retrospectively analyzed. Treatment effects were evaluated after 2 cycles of induction therapy and after CCRT by contrast-enhanced CT scans and esophagograms, followed by subsequent evaluations every 3 months post-treatment.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet
January 2025
Department of Diagnostic and Interventional Radiology, University of Pisa School of Medicine, Pisa, Italy.
Background: Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.
Methods: In this multiregional, randomised, double-blind, placebo-controlled, phase 3 study (EMERALD-1), adults aged 18 years or older with unresectable hepatocellular carcinoma amenable to embolisation, an Eastern Cooperative Oncology Group performance status of 0 or 1 at enrolment, and at least one measurable intrahepatic lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) were enrolled at 157 medical sites including research centres and general and specialist hospitals in 18 countries.
Preoperative management of patients with oesophageal cancer: expert recommendations.
Cir Esp (Engl Ed)
December 2024
Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario San Pedro, Logroño, Spain.
The aim of this work is to establish recommendations for the preoperative evaluation and selection of patients with malignant oesophageal neoplasms, who are candidates for surgical resection with curative intent, based on the consensus established by a group of experts. Using the Delphi methodolgy and after 2 rounds of evaluation, responses were obtained from 37 experts to 47 questions about the preoperative management of oesophageal cancer, considering consensus if there was a mean score greater than 8 (range between 0 to 10). Of the respondents, 54% were women, with a mean age of 50.
View Article and Find Full Text PDFPrognosis of radiotherapy for esophageal cancer in elderly patients exceeding seventy-five years old.
World J Gastrointest Oncol
December 2024
Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China.
Background: Esophageal cancer (EC) often occurs in the elderly, with approximately 33% of patients aged ≥ 75 years at the time of diagnosis.
Aim: To evaluate the prognostic factors for radiotherapy (RT) in elderly patients with unresectable EC.
Methods: We retrospectively analyzed the clinical characteristics, toxic reactions, and survival information of EC patients aged ≥ 75 years who underwent intensity-modulated RT at Lu'an Hospital of Anhui Medical University between January 2016 and September 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!